RECRUITING

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.

Official Title

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

Quick Facts

Study Start:2017-06-22
Study Completion:2027-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03297775

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:45 Years to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. ≥ 45years old
  2. 2. Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria
  1. 1. Inability to give informed consent
  2. 2. Pregnant women
  3. 3. History of interstitial lung disease
  4. 4. Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc.
  5. 5. Subjects over the age of 90 years old or less than 45 years old

Contacts and Locations

Study Contact

Haylie A Lengel
CONTACT
970-376-8303
haylie.lengel@cuanschutz.edu
Joyce S Lee, MD
CONTACT
303-724-6109
joyce.lee@ucdenver.edu

Principal Investigator

Joyce S Lee, MD
PRINCIPAL_INVESTIGATOR
University of Colorado, Denver

Study Locations (Sites)

University of Colorado - Anschutz Medical Campus
Aurora, Colorado, 80045
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Joyce S Lee, MD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-06-22
Study Completion Date2027-06

Study Record Updates

Study Start Date2017-06-22
Study Completion Date2027-06

Terms related to this study

Keywords Provided by Researchers

  • Rheumatoid Arthritis
  • RA
  • Interstitial Lung Disease
  • ILD
  • lung disease
  • connective tissue disease
  • CTD
  • idiopathic pulmonary fibrosis
  • IPF
  • airways disease

Additional Relevant MeSH Terms

  • Rheumatoid Arthritis
  • Interstitial Lung Disease